Strategas Macro Momentum ETF’s 3.98% Medtronic Exposure Slides After $550M Deal
Strategas Macro Momentum ETF holds 3.98% of its portfolio in Medtronic, whose shares fell 1.07% to $90.36 after unveiling a $550 million acquisition of Scientia Vascular. Weak performance in Medtronic and broader market declines may pressure the ETF's momentum-focused strategy in the near term.
1. ETF Overview
Strategas Macro Momentum ETF employs a systematic momentum strategy across U.S. large-cap equities, dynamically adjusting weights based on relative strength signals. The fund targets sectors showing upward price trends, with healthcare represented through key holdings like Medtronic.
2. Medtronic Exposure
Medtronic constitutes 3.98% of the ETF’s assets, marking it as a significant healthcare stake. Shares declined 1.07% to $90.36 following the announcement of a $550 million acquisition of Scientia Vascular, creating a drag on the fund’s performance.
3. Performance Outlook
The pullback in Medtronic, combined with broader market weakness, could dampen the ETF’s momentum readings if similar patterns emerge in other top holdings. Investors should monitor upcoming corporate catalysts and shifting technical indicators to gauge the ETF’s directional bias.